CTSO:NASDAQ
Cytosorbents Corp
US$0.65
arrow_upward
+2.68%(+0.017) 1D
4월 23일, 오후 4시 0분 1초 GMT-4 · USD
search
모든 종목 코드
1D
5D
1M
6M
YTD
1Y
5Y
최대
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_autoCTSO의 주요 통계 생성 중...
시가
US$0.63
고가
US$0.65
저가
US$0.61
시가총액
4068.78만
평균 거래량
9.98만
거래량
0.00
52주 최고가
US$1.39
52주 최저가
US$0.50
EPS
-US$0.13
베타
1.47
유통 주식수
6280.40만
직원 수
129
뉴스 기사
웹 소스 기반
Simply Wall Street
·
17분 전
Roper Technologies (ROP) Margin Decline Tests Bullish AI Growth Narrative Heading Into Q1 2026
Yahoo Finance
·
34분 전
Charter’s (NASDAQ:CHTR) Q1 CY2026 Earnings Results: Revenue In Line With Expectations
Business Wire
·
43분 전
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Investing.com 한국어
·
48분 전
트릴러 그룹, 나스닥 최저 입찰가 규정 미준수로 상장폐지 통보
프로필
CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey.
CytoSorbents sells a cytokine adsorbing column — a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful inflammatory mediators like Cytokines, Bilirubin, Myoglobin from the blood.
The use of hemoperfusion columns is generally limited to patients who are critically ill in high-resource counties, and they require a patient to be connected to a hemofiltration system such as Dialysis, Hemofiltration Cardiopulmonary bypass or ECMO. Other blood purification devices are using different technologies with different performance parameters. This is including polymyxin B hemoperfusion columns, which failed to show significance in a clinical trial for sepsis. The CytoSorb technology has actually the largest body of clinical data confirming safety and efficacy. Clinicaltrials.gov is giving an overview over running research projects.
CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins. Wikipedia
Cytosorbents Corp에 관한 정보